Toxicity and response to ipilimumab and nivolumab in older patients with metastatic melanoma: A multicentre retrospective analysis.
combination
elderly
geriatrics
immunotherapy
melanoma
Journal
Pigment cell & melanoma research
ISSN: 1755-148X
Titre abrégé: Pigment Cell Melanoma Res
Pays: England
ID NLM: 101318927
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
27
07
2022
received:
11
04
2022
accepted:
17
08
2022
pubmed:
7
9
2022
medline:
29
10
2022
entrez:
6
9
2022
Statut:
ppublish
Résumé
Combination immunotherapy with nivolumab and ipilimumab is an effective therapy in the treatment of metastatic melanoma, however, its benefit in older patients is unclear. A multicentre retrospective study was performed to compare the efficacy and toxicity of combination immunotherapy in metastatic melanoma in patients ≥65 years versus <65 years, and complications of steroids used to manage toxicity. One hundred and thirty-nine patients were included with 52 patients ≥65 years (median age: 70; range: 65-83) and 87 patients <65 years (median age: 52; range: 22-64). Median overall survival was similar in patients ≥65 years versus <65 years (14.9 vs. 17.3 months p = .58). Median progression-free survival was also similar in both groups (7.1 vs. 6.9 months p = .79), as was overall response rate (48.1% vs. 44.8% p = .73). Age was not associated with a difference in overall survival on multivariate analysis. There was similar rates of Grade 3 or higher adverse events in patients ≥65 years versus <65 years (50% vs. 49% p = 1.0) and discontinuation rates secondary to toxicity (55.8% vs. 56% p = 1.0). Median duration of steroids used to treat adverse events was similar (11 vs. 12 weeks p = .46). Complications of steroids requiring inpatient admission was numerically higher in the older patients (41.3% vs. 20.4% p = .07). Patients ≥65 years received similar benefit from combination immunotherapy in comparison to their younger counterparts with similar toxicity.
Substances chimiques
Ipilimumab
0
Nivolumab
31YO63LBSN
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
587-594Informations de copyright
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Betof, A. S., Nipp, R. D., Giobbie-Hurder, A., Johnpulle, R. A. N., Rubin, K., Rubinstein, S. M., Flaherty, K. T., Lawrence, D. P., Johnson, D. B., & Sullivan, R. J. (2017). Impact of age on outcomes with immunotherapy for patients with melanoma. The Oncologist, 22(8), 963-971.
Cancer Australia [Internet]. (2019). Cancer Incidence. Available January, 2021, from, https://ncci.canceraustralia.gov.au/diagnosis/cancer-incidence/cancer-incidence
Cybulska-Stopa, B., Ziętek, M., Kamińska-Winciorek, G., Czarnecka, A. M., Piejko, K., Galus, Ł., Ziółkowska, B., Kieszko, S., Kempa-Kamińska, N., Calik, J., Zemełka, T., Kubiatowski, T., Suwiński, R., Mackiewicz, J., & Rutkowski, P. (2021). Anti-programmed cell death-1 therapy in octogenarian and nonagenarian advanced/metastatic melanoma patients. Melanoma Research, 31(1), 49-57.
Elias, R., Giobbie-Hurder, A., McCleary, N. J., Ott, P., Hodi, F. S., & Rahma, O. (2018). Efficacy of PD-1 & PD-L1 inhibitors in older adults: A meta-analysis. Journal for Immunotherapy of Cancer, 6(1), 26.
de Glas, N. A., Bastiaannet, E., van den Bos, F., Mooijaart, S. P., van der Veldt, A. A. M., Suijkerbuijk, K. P. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J.-W. B., Haanen, J. B. A. G., Hospers, G. A. P., Jalving, H., Piersma, D., van Rijn, R. S., Ten Tije, A. J., Vreugdenhil, G., … Kapiteijn, E. W. (2021). Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors. Cancers (Basel), 13(11), 2826.
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., Akerley, W., van den Eertwegh, A. J. M., Lutzky, J., Lorigan, P., Vaubel, J. M., Linette, G. P., Hogg, D., Ottensmeier, C. H., Lebbé, C., … Urba, W. J. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine, 363(8), 711-723.
Howell, A. V., Gebregziabher, M., Thiers, B. H., Paulos, C. M., Wrangle, J. M., Hunt, K. J., & Wallace, K. (2021). Immune checkpoint inhibitors retain effectiveness in older patients with cutaneous metastatic melanoma. Journal of Geriatric Oncology, 12(3), 394-401.
Iacono, D., Vitale, M. G., Basile, D., Pelizzari, G., Cinausero, M., Poletto, E., Pascoletti, G., & Minisini, A. M. (2021). Immunotherapy for older patients with melanoma: From darkness to light? Pigment Cell & Melanoma Research, 34(3), 550-563.
Ibrahim, T., Mateus, C., Baz, M., & Robert, C. (2018). Older melanoma patients aged 75 and above retain responsiveness to anti-PD1 therapy: Results of a retrospective single-institution cohort study. Cancer Immunology, Immunotherapy, 67(10), 1571-1578.
Jain, V., Hwang, W. T., Venigalla, S., Nead, K. T., Lukens, J. N., Mitchell, T. C., & Shabason, J. E. (2020). Association of age with efficacy of immunotherapy in metastatic melanoma. The Oncologist, 25(2), e381-e385.
Kasanen, H., Hernberg, M., Mäkelä, S., Brück, O., Juteau, S., Kohtamäki, L., Ilander, M., Mustjoki, S., & Kreutzman, A. (2020). Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients. Cancer Immunology, Immunotherapy, 69(5), 717-730.
Kugel, C. H., Douglass, S. M., Webster, M. R., Kaur, A., Liu, Q., Yin, X., Weiss, S. A., Darvishian, F., Al-Rohil, R. N., Ndoye, A., Behera, R., Alicea, G. M., Ecker, B. L., Fane, M., Allegrezza, M. J., Svoronos, N., Kumar, V., Wang, D. Y., Somasundaram, R., … Weeraratna, A. T. (2018). Age correlates with response to anti-PD1, reflecting age-related differences in Intratumoral effector and regulatory T-cell populations. Clinical Cancer Research, 24(21), 5347-5356.
Larkin, J., Hodi, F. S., & Wolchok, J. D. (2015). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. The New England Journal of Medicine, 373(13), 1270-1271.
Mason, R., Dearden, H. C., Nguyen, B., Soon, J. A., Smith, J. L., Randhawa, M., Mant, A., Warburton, L., Lo, S., Meniawy, T., Guminski, A., Parente, P., Ali, S., Haydon, A., Long, G. V., Carlino, M. S., Millward, M., Atkinson, V. G., & Menzies, A. M. (2020). Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma. Pigment Cell and Melanoma Research, 33(2), 358-365.
Muss, H. B., Berry, D. A., Cirrincione, C., Budman, D. R., Henderson, I. C., Citron, M. L., Norton, L., Winer, E. P., Hudis, C. A., & Cancer and Leukemia Group B Experience. (2007). Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: The cancer and leukemia group B experience. Journal of Clinical Oncology, 25(24), 3699-3704.
Neugut, A. I., Matasar, M., Wang, X., McBride, R., Jacobson, J. S., Tsai, W. Y., Grann, V. R., & Hershman, D. L. (2006). Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. Journal of Clinical Oncology, 24(15), 2368-2375.
Perier-Muzet, M., Gatt, E., Péron, J., Falandry, C., Amini-Adlé, M., Thomas, L., Dalle, S., & Boespflug, A. (2018). Association of Immunotherapy with Overall Survival in elderly patients with melanoma. JAMA Dermatology, 154(1), 82-87.
Ridolfi, L., de Rosa, F., Petracci, E., Tanda, E. T., Marra, E., Pigozzo, J., Marconcini, R., Guida, M., Cappellini, G. C. A., Gallizzi, G., Occelli, M., Pala, L., Gambale, E., Bersanelli, M., Galdo, G., Cortellini, A., Morgese, F., Zoratto, F., Stucci, L. S., … Guidoboni, M. (2020). Anti-PD1 antibodies in patients aged ≥75 years with metastatic melanoma: A retrospective multicentre study. Journal of Geriatric Oncology, 11(3), 515-522.
Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J. D., Joshua, A. M., Hwu, W. J., Weber, J. S., Gangadhar, T. C., Joseph, R. W., Dronca, R., Patnaik, A., Zarour, H., Kefford, R., Hersey, P., Zhang, J., Anderson, J., Diede, S. J., Ebbinghaus, S., & Hodi, F. S. (2018). Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. Journal of Clinical Oncology, 36(17), 1668-1674.
Sakuma, Y., Katoh, T., Owada, K., Suzuki, H., Sakurai, K., Eiro, M., Asahi, K., & Watanabe, T. (2005). Initial functional status predicts infections during steroid therapy for renal diseases. Clinical Nephrology, 63(2), 68-73.
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., Larkin, J., Lorigan, P., Neyns, B., Blank, C., Petrella, T. M., Hamid, O., Zhou, H., Ebbinghaus, S., Ibrahim, N., & Robert, C. (2017). Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet, 390(10105), 1853-1862.
Sugiyama, T., Suzuki, S., Yoshida, T., Mayama, T., Hashimoto, N., Suyama, K., Tanaka, T., Sueishi, M., & Tatsuno, I. (2011). Age, initial dose and dose increase are independent risk factors for symptomatic vertebral fractures in glucocorticoid-treated male patients. Internal Medicine, 50(8), 817-824.
Tawbi, H. A., Forsyth, P. A., Hodi, F. S., Algazi, A. P., Hamid, O., Lao, C. D., Moschos, S. J., Atkins, M. B., Lewis, K., Postow, M. A., Thomas, R. P., Glaspy, J., Jang, S., Khushalani, N. I., Pavlick, A. C., Ernstoff, M. S., Reardon, D. A., Kudchadkar, R., Tarhini, A., … Margolin, K. A. (2021). Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): Final results of an open-label, multicentre, phase 2 study. The Lancet Oncology, 22(12), 1692-1704.